This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2011 by Deise de Boni Monteiro de Carvalho, Hospital Federal de Bonsucesso.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Deise de Boni Monteiro de Carvalho, Hospital Federal de Bonsucesso Identifier:
First received: October 11, 2011
Last updated: October 19, 2011
Last verified: October 2011
The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.

Condition Intervention Phase
Kidney Transplant Immunosuppression Drug: Everolimus Drug: calcineurin inhibitor Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor

Resource links provided by NLM:

Further study details as provided by Deise de Boni Monteiro de Carvalho, Hospital Federal de Bonsucesso:

Primary Outcome Measures:
  • Change from Baseline in Creatinine Clearance at 24 months [ Time Frame: baseline and two years ]
    The primary objective is to demonstrate the effectiveness and non-inferiority of treatment with everolimus, by assessing renal function, in comparison with the use of calcineurin inhibitor.

Secondary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: baseline and two years ]
    The secondary objective is to demonstrate the safety by comparing rejection episodes, graft loss, infection, cancer and death in the control group

Estimated Enrollment: 30
Study Start Date: November 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus Drug: Everolimus
Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
Other Name: Certican
Active Comparator: calcineurin inhibitor Drug: calcineurin inhibitor
Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
Other Name: Tacrolimus, Cyclosporin, NeoOral, Prograf

Detailed Description:
The patient who met the inclusion and exclusion criteria will be included in the study and randomized into two groups in the third month post transplant, they will be in use of tacrolimus, corticosteroids and Mycophenolate sodium. The group 1 will undergo a conversion from calcineurin inhibitor to Everolimus within 1 day (overnight), group 2 will be maintained with the initial immunosuppression. We will start Everolimus at 1 mg 2x/day and three days after the beginning we will adjust the dose by the serum levels, which will be kept in 6 to 10ng/dL. The doses of corticosteroids and Mycophenolate sodium will be retained. There will be performed renal biopsies at randomization and after 12 months. The glomerular filtration rate will be calculated monthly using the MDRD.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients aged from 18 to 65 years old
  • First transplantation recipients
  • PRA < 30%
  • Living or cadaveric donor
  • Stable renal function
  • Patients not pregnant or breastfeeding , where pregnancy is defined as the woman status from conception to gestation conclusion, through a positive beta hCG test (>5mUI/mL)
  • Provided written informed consent form

Exclusion Criteria:

  • Cadaveric donor with expanded criterion
  • Multiple organs transplantation
  • Kidney cold ischemia time > 24 hours
  • Severe rejection episode - Banf >IIA
  • Glomerular filtration rate < 35mL/min
  • Presence of hard to treat dyslipidemia - severe hypercholesterolemia (>350mg/dL) or hypertriglyceridemia (>500mg/dL)
  • Proteinuria > 800mg/24h
  • Patients with history of malignancy of any organic system, treated or not, within 5 years, with or without evidence of local recurrence or metastases, other than localized basal cell carcinoma
  • Female with childbearing potential without using a reliable contraceptive method.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01455649

Contact: Deise BM Carvalho, MD +55 (21) 99876059

Hospital federal de Bonsucesso Not yet recruiting
Rio de Janeiro, Brazil, 21041-030
Sponsors and Collaborators
Deise de Boni Monteiro de Carvalho
Study Chair: Francisco G Miloski, MD Physician
Study Chair: Tereza Matuck, MD Chief of the Nephrology Department
Study Chair: Regina Sousa Head Nurse of The Nephrology Department
  More Information

Responsible Party: Deise de Boni Monteiro de Carvalho, Organ Transplant Technical Manager, Hospital Federal de Bonsucesso Identifier: NCT01455649     History of Changes
Other Study ID Numbers: CRAD001ABR17T
Study First Received: October 11, 2011
Last Updated: October 19, 2011

Keywords provided by Deise de Boni Monteiro de Carvalho, Hospital Federal de Bonsucesso:
Graft function

Additional relevant MeSH terms:
Calcineurin Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017